FIgure S2 from Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer
Julia Judd(Palmetto Hematology Oncology), Hossein Borghaei(Fox Chase Cancer Center), Hirva Mamdani(Wayne State University), Ari M. Vanderwalde(West Cancer Center), W. Michael Korn(Itasca Community College), Stephen V. Liu(Georgetown University), Alexander I. Spira(Virginia Cancer Specialists), Sachin Gopalkrishna Pai(USA Mitchell Cancer Institute), Nagla Abdel Karim(University of Cincinnati), Misako Nagasaka(University of California, Irvine), Edward S. Kim(The University of Texas MD Anderson Cancer Center), Gilberto Lopes(University of Miami), Jorge J. Nieva(University of Southern California), Yasmine Baca(Caris Life Sciences (United States)), Mark A. Socinski(Florida Hospital Cancer Institute), Joanne Xiu(Caris Life Sciences (United States)), Chukwuemeka Ikpeazu(Sylvester Comprehensive Cancer Center), Abdul Rafeh Naqash(Oklahoma City University), Chul Kim(Georgetown University), Antoinette J. Wozniak(Wayne State University), Hina Khan, Luis E. Raez(Florida International University)
Cited by 0
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k